Acuity Reports Positive Phase II Data for AMD Drug; Eyes Phase III in Mid-'07, NDA in Mid-'09 | GenomeWeb
Acuity Pharmaceuticals this week released additional results from an uncontrolled phase II trial of its siRNA-based therapy for wet age-related macular degeneration, reporting that its drug was safe and produced dose-dependent decreases of the lesions that characterize the condition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.